Nanovesicular drug delivery system: A novel and emerging approach for burn management

Burns are a leading cause of trauma, affecting over 11 million people globally each year, resulting in significant pain, infections, and delayed recovery. While traditional burn treatments are effective, they have limitations, leading to the development of nanovesicular drug delivery systems. These systems, including liposomes, niosomes, ethosomes, cubosomes and phytosomes provide targeted, controlled drug release, improved drug stability, deeper skin penetration, and prolonged effects. They can also deliver a range of therapeutic agents, such as antimicrobial, anti-inflammatory drugs, and growth factors, enhancing healing and reducing complications. Despite their potential, no clinical studies have yet explored these systems for burn treatment, and such products are not yet available on the market. Successful clinical trials could make these treatments widely available, offering a promising opportunity for research and development. This review explores the potential, benefits, challenges, and future applications of nanovesicular drug delivery systems in burn care.